Early West Nile surge in Twin Cities mosquitoes has officials urging caution
The Metropolitan Mosquito Control District said pests in all seven counties it covers have tested positive for the disease.
Positivity rate is also higher than normal for July — a quarter of the mosquito pools tested last week came back positive for West Nile. That is "more typical with late-August when the mosquito populations are winding down," the district said.
The mosquito species that infects humans most often is "active in some of the highest numbers recorded by MMCD," the organization said.
There has only been one human case of West Nile virus in Minnesota so far this year. Most people who contract the disease have no symptoms.
Officials recommend using insect repellent, wearing long, loose-fitting, light-colored clothes, getting rid of stagnant water on your property and staying inside during peak mosquito activity hours.
The MMCD covers Hennepin, Carver, Scott, Dakota, Washington, Ramsey and Anoka counties.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
BioMendics Launches TAMES-02 Clinical Trial for Innovative Epidermolysis Bullosa Simplex Therapy
BioMendics Launches Pivotal TAMES-02 Clinical Trial to Advance TolaSure™ for EB Simplex Patients ROOTSTOWN, Ohio, August 07, 2025--(BUSINESS WIRE)--BioMendics, a clinical-stage biopharmaceutical company focused on rare skin diseases, today announced the launch of the TAMES-02 clinical trial—a multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of TolaSure™, a first-in-class topical therapy for patients with generalized intermediate to severe Epidermolysis Bullosa Simplex (EB Simplex). EB Simplex is a rare, inherited skin disorder that causes painful blistering due to fragile skin, affecting an estimated 30,000 to 50,000 individuals worldwide. With current treatment limited to wound care and infection control, patients and families face a lifelong battle without disease-modifying options. TolaSure, developed by BioMendics, aims to change that reality by targeting the mutant keratins that underlie skin fragility, offering a novel mechanism to reduce blister burden and improve quality of life. The TAMES-02 trial builds on the success of the earlier TAMES-01 study, which demonstrated TolaSure's safety and efficacy in adult patients. Dr. Joyce Teng, Principal Investigator at Stanford University, shared: "Our early studies with TolaSure showed meaningful reduction in blistering, which is incredibly encouraging for the EB Simplex community. Clinical research in rare skin diseases requires collaboration with companies like BioMendics and patient advocacy groups like debra of America to accelerate progress toward transformative therapies. Our shared goal is to bring hope and healing to families who have had so few options for so long." TAMES-02 is being conducted in partnership with Stanford University School of Medicine and Northwestern University Feinberg School of Medicine—two globally recognized leaders in dermatology research. The trial will evaluate TolaSure in patients aged 4 and older and includes a 2-month double-blind, placebo-controlled phase, followed by a 2-month open-label phase where all participants receive TolaSure, and a 6-month follow-up. Importantly, the trial allows patients to treat plantar (foot) blistering—a major source of pain and disability for those living with EB Simplex. Dr. Amy Paller, Principal Investigator at Northwestern University, added: "TAMES-02 is a vital next step. The collaboration with BioMendics and Stanford enables us to rigorously evaluate this therapy and, hopefully, bring real progress to patients who have had limited options for far too long." "We're really excited to be able to cover travel cost to bring patients in from all over the United States and internationally," said Dr. Aleesha McCormick Senior clinical research scientist at BioMendics. "EB Simplex patients don't all live close to an Academic Medical Center like Stanford and Northwestern and our goal is to help as many patients be able to participate in the study as possible. Our study design also lets us recruit slightly less severe patients that may not have flared enough to be eligible for other clinical studies." "Our mission is to bring meaningful therapies to patients living with rare diseases like EB Simplex—conditions that have been overlooked for too long," said Dr. Karen M. McGuire, CEO and Founder of BioMendics. "With TolaSure, we're targeting the root cause of blistering by reinforcing fragile keratinocytes. The TAMES-02 trial is a critical step toward proving safety and efficacy. If successful, we'll seek strategic partnerships to help accelerate development and deliver this treatment to patients as quickly as possible. We also see strong potential for TolaSure in other rare keratin disorders such as pachyonychia congenita and epidermolytic ichthyosis." TAMES-02 reflects BioMendics' ongoing commitment to developing innovative, targeted treatments for rare skin disorders and is currently open for patient enrollment. About BioMendics: For more information about BioMendics please visit our website ( BioMendics is proud to be a REDIzone company at Northeast Ohio Medical University (NEOMED). The REDIzone (Research, Entrepreneurship, Discovery, and Innovation Zone) supports local life science and biomedical entrepreneurs by providing access to NEOMED's resources, expertise, and connections to the region's innovation ecosystem. This partnership has been instrumental in advancing TolaSure from research to clinical development. View source version on Contacts To learn more or inquire about participation, visit or contact the study sites below: Stanford University Dermatology Dr. Joyce Teng (Principal Investigator)Contact: Thomas Buschbacher – tbusch@ Questions about participant rights: 1-866-680-2906 Northwestern University Dermatology Dr. Amy Paller (Principal Investigator)Contact: Dr. Lydia Rabbaa Khabbaz – Questions about participant rights: 312-503-7110 BioMendics, LLC Dr. Karen M. McGuire, CEO & Founder – kmcguire@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
Avidity (RNA) Gets 26% Jump on Potential Takeover
We recently published . Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the best-performing stocks on Wednesday. Avidity Biosciences rallied for a third day on Wednesday, jumping 26.14 percent to close at $48.26 as investors gobbled up shares following reports that it received an acquisition bid from Swiss drugmaker Novartis AG (NYSE:NVS). A report by the Financial Times, citing people privy to the matter, said that Novartis AG (NYSE:NVS) offered Avidity Biosciences, Inc. (NASDAQ:RNA) to acquire the company, in line with the former's plans to boost its pipeline of medicines targeting rare genetic disorders. Meanwhile, the report said that Avidity Biosciences, Inc. (NASDAQ:RNA) was mulling over the offer, although the talks could still collapse as other companies have emerged with separate takeover offers. Late last month, Avidity Biosciences, Inc. (NASDAQ:RNA) secured a Breakthrough Therapy designation from the Food and Drug Administration for its del-zota treatment for Duchenne muscular dystrophy (DMD) in patients with DMD44. DMD is a rare genetic condition characterized by progressive muscle damage and weakness due to the loss of dystrophin protein that typically starts at a young age. Del-zota, on the other hand, was designed to deliver phosphorodiamidate morpholino oligomers (PMOs) to skeletal muscle and heart tissue to specifically skip exon 44 of the dystrophin gene and enable production of near-full length dystrophin. While we acknowledge the potential of RNA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
Yahoo
2 minutes ago
- Yahoo
New Jane Doe Brings Allegations of Sexual Abuse against Tri-Cities OB-GYN Mark Mulholland
Providence St. Joseph Health and Kadlec Regional Medical Center masked numerous patient complaints for more than two decades SEATTLE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- A new lawsuit filed by Jane Doe 100 in King County Superior Court – who is represented by Chicago-based attorney Tamara Holder and Elizabeth Hanley of Schroeter Goldmark & Bender in Seattle – adds to the growing number of female patients who allege they were physically and sexually abused Mark E. Mulholland, a Tri-Cities OBGYN who worked for Providence St. Joseph Health and Kadlec Regional Medical Center, in Richland, Washington, from 1999 through May or June 2025. Jane Doe 100 alleges that during an appointment in 2022, Mulholland performed a gloveless breast 'exam;' he aggressively opened up her legs and shoved a metal speculum into her vagina despite her explicit request for a plastic speculum; he placed his gloveless hand on her inner thigh; he told her something to the effect of, 'You're perfect down there;' and, he touched her shoulder, winked at her, and asked if she was single. According to Jane Doe's claim, it wasn't until she began hearing accounts from other survivors who have come forward to share their stories of sexual abuse at the hands of Mulholland, that she fully realized she, too, is a victim as well. Even more alarming, Jane Doe 100 further alleges that, since as early as 2003, Kadlec received numerous patient complaints about Mulholland both before and after her appointment, including allegations of unexplained rectal 'exams;' fat shaming; gloveless pelvic 'exams;' using excessive force and causing pain, bleeding, and unnecessary wounding to female patients' most private parts of their bodies. Attorneys Tamara Holder and Elizabeth Hanley have extensive experience in securing justice for victims of gender-based violence, sexual abuse and harassment. Holder spearheaded the multi-plaintiff litigation against Chicago-area OBGYN and convicted sex offender Fabio Ortega; and Hanley regularly represents survivors in sexual assault and discrimination cases, notably against powerful entities that fail to prevent systemic abuse. 'As a Kamiakin High School graduate, just like Mulholland, I am devastated to learn that, not only did he allegedly abuse so many trusting female patients, but that one of the few medical centers in the area lured women to him, only for them to be violently abused, and then the women were ignored when they complained. We are devoted to not only obtaining justice for our clients but also to exposing how Providence and Kadlec profited off of Mulholland's alleged sex crimes and abuses of his position of trust and power.. I am excited to work with Elizabeth Hanley and try as many cases as we can to ensure that these institutions' conduct is fully exposed to the community,' said Holder. 'This doctor's actions represent a horrifying betrayal of trust—and the healthcare institutions that enabled his abuse must also be held accountable. To the survivors who were ignored, dismissed, or silenced: Your courage in coming forward is what will bring justice for Mulholland's abuse, and will protect others from ever enduring this kind of violation again,' Hanley added. Jane Doe 100's lawsuit accuses the defendants of sex-based discrimination, failure to protect patients, and institutional negligence. If you or someone you know has information about Mark Mulholland or the institutions where he worked, please reach out to or SGB as soon as possible. Unfortunately, the amount of time to come forward is not unlimited. To learn more about the firms' work representing survivors of abuse and discrimination, visit: or About Tamara Holder Law:Tamara Holder is an international women's rights and institutional abuse attorney. Her boutique practice – Tamara Holder Law – focuses on sex trafficking, doctor-patient sexual abuse, fraternity rape, workplace sexual harassment, and beyond. For nearly a decade, Holder was a Fox News Channel legal analyst. In addition to being a legal and media advocate, she has also testified before Congress, and obtained legislation on behalf of her abused clients. About Schroeter Goldmark & Bender: Founded in 1969, Schroeter Goldmark & Bender (SGB) is a nationally recognized law firm based in Seattle that holds the most powerful companies, government agencies, and people accountable for their wrongdoing. SGB specializes in representing injured persons in asbestos and mesothelioma, catastrophic injury, brain/spinal cord injury, medical malpractice, unsafe products, wrongful death, sexual assault and harassment, as well as individual and class action employment cases. The firm believes the law is a force of good and is committed to achieving justice for people who have been harmed. Find more at CONTACT: MEDIA CONTACTS press@ (312) 440-9000 Kristi@ (206) 466-2702
